Literature DB >> 33490120

Growth Factor Deregulation and Emerging Role of Phosphatases in Diabetic Peripheral Artery Disease.

Clément Mercier1, Marina Rousseau1, Pedro Geraldes1.   

Abstract

Peripheral artery disease is caused by atherosclerosis of lower extremity arteries leading to the loss of blood perfusion and subsequent critical ischemia. The presence of diabetes mellitus is an important risk factor that greatly increases the incidence, the progression and the severity of the disease. In addition to accelerated disease progression, diabetic patients are also more susceptible to develop serious impairment of their walking abilities through an increased risk of lower limb amputation. Hyperglycemia is known to alter the physiological development of collateral arteries in response to ischemia. Deregulation in the production of several critical pro-angiogenic factors has been reported in diabetes along with vascular cell unresponsiveness in initiating angiogenic processes. Among the multiple molecular mechanisms involved in the angiogenic response, protein tyrosine phosphatases are potent regulators by dephosphorylating pro-angiogenic tyrosine kinase receptors. However, evidence has indicated that diabetes-induced deregulation of phosphatases contributes to the progression of several micro and macrovascular complications. This review provides an overview of growth factor alterations in the context of diabetes and peripheral artery disease, as well as a description of the role of phosphatases in the regulation of angiogenic pathways followed by an analysis of the effects of hyperglycemia on the modulation of protein tyrosine phosphatase expression and activity. Knowledge of the role of phosphatases in diabetic peripheral artery disease will help the development of future therapeutics to locally regulate phosphatases and improve angiogenesis.
Copyright © 2021 Mercier, Rousseau and Geraldes.

Entities:  

Keywords:  diabetes; endothelia cell dysfunction; growth factor; peripheral arterial disease; phosphatase

Year:  2021        PMID: 33490120      PMCID: PMC7817696          DOI: 10.3389/fcvm.2020.619612

Source DB:  PubMed          Journal:  Front Cardiovasc Med        ISSN: 2297-055X


  131 in total

1.  Diabetic microangiopathy in ischemic limb is a disease of disturbance of the platelet-derived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors.

Authors:  Mitsugu Tanii; Yoshikazu Yonemitsu; Takaaki Fujii; Yasunori Shikada; Ri-ichiro Kohno; Mitsuho Onimaru; Shinji Okano; Makoto Inoue; Mamoru Hasegawa; Toshihiro Onohara; Yoshihiko Maehara; Katsuo Sueishi
Journal:  Circ Res       Date:  2005-11-23       Impact factor: 17.367

2.  Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice.

Authors:  Ali H Amin; Zakaria Y Abd Elmageed; Devika Nair; Megan I Partyka; Philip J Kadowitz; Souad Belmadani; Khalid Matrougui
Journal:  Lab Invest       Date:  2010-05-03       Impact factor: 5.662

3.  High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation.

Authors:  N Begum; L Ragolia
Journal:  Am J Physiol Cell Physiol       Date:  2000-01       Impact factor: 4.249

4.  PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells.

Authors:  Anthony A Lanahan; Diana Lech; Alexandre Dubrac; Jiasheng Zhang; Zhen W Zhuang; Anne Eichmann; Michael Simons
Journal:  Circulation       Date:  2014-06-30       Impact factor: 29.690

5.  Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus.

Authors:  Gian Paolo Fadini; Marta Miorin; Monica Facco; Sondra Bonamico; Ilenia Baesso; Franco Grego; Mirko Menegolo; Saula Vigili de Kreutzenberg; Antonio Tiengo; Carlo Agostini; Angelo Avogaro
Journal:  J Am Coll Cardiol       Date:  2005-05-03       Impact factor: 24.094

6.  Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.

Authors:  Andrew D Blann; Funmi M Belgore; Charles N McCollum; Stanley Silverman; Peck Lin Lip; Gregory Y H Lip
Journal:  Clin Sci (Lond)       Date:  2002-02       Impact factor: 6.124

7.  Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression.

Authors:  Patrick Fournier; Sylvie Dussault; Alfredo Fusco; Alain Rivard; Isabelle Royal
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

8.  Altered SDF-1-mediated differentiation of bone marrow-derived endothelial progenitor cells in diabetes mellitus.

Authors:  Elena De Falco; Daniele Avitabile; Pierangela Totta; Stefania Straino; Francesco Spallotta; Chiara Cencioni; Anna Rita Torella; Roberto Rizzi; Daniele Porcelli; Antonella Zacheo; Luca Di Vito; Giulio Pompilio; Monica Napolitano; Guido Melillo; Maurizio C Capogrossi; Maurizio Pesce
Journal:  J Cell Mol Med       Date:  2009-09       Impact factor: 5.310

9.  Inhibition of protein kinase C enhances angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cells.

Authors:  Junji Moriya; Napoleone Ferrara
Journal:  Cardiovasc Diabetol       Date:  2015-02-07       Impact factor: 9.951

10.  Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*.

Authors:  Resham Bhattacharya; Junhye Kwon; Enfeng Wang; Priyabrata Mukherjee; Debabrata Mukhopadhyay
Journal:  J Mol Signal       Date:  2008-03-31
View more
  2 in total

Review 1.  Update on the pathophysiology and medical treatment of peripheral artery disease.

Authors:  Jonathan Golledge
Journal:  Nat Rev Cardiol       Date:  2022-01-07       Impact factor: 32.419

2.  Effect of Revascularization on Intramuscular Vascular Endothelial Growth Factor Levels in Peripheral Arterial Disease.

Authors:  Larissa Schawe; Ben Raude; Jan Christoph Carstens; Irene Hinterseher; Raphael Donatus Hein; Safwan Omran; Gilles Berger; Nina A Hering; Matthias Buerger; Andreas Greiner; Jan Paul Frese
Journal:  Biomedicines       Date:  2022-02-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.